



Contents lists available at ScienceDirect

International Journal of Infectious Diseases

journal homepage: www.elsevier.com/locate/ijid



INTERNATIONAL
SOCIETY
FOR INFECTIOUS
DISEASES

Time to embrace access programmes for medicines: lessons from the South African flucytosine access programme



Amir Shroufi^{a,*}, Nelesh P. Govender^b, Graeme Meintjes^c, John Black^d, Jeremy Nel^e, Mahomed-Yunus S. Moosa^f, Colin Menezes^{e,g}, Halima Dawood^f, Douglas Wilson^h, Laura Trivino Duran^a, Olawale Ajoseⁱ, Richard A. Murphy^{j,k}, Thomas Harrison^{l,m}, Angela Loyseⁿ, Carol Ruffell^{i,o}, Gilles Van Cutsem^{a,p}

^a Doctors Without Borders South Africa, Johannesburg, South Africa

^b National Institute for Communicable Diseases, A Division of the National Health Laboratory Service and University of the Witwatersrand, Johannesburg, South Africa

^c University of Cape Town, Western Cape, South Africa

^d Livingstone Hospital, Eastern Cape, South Africa

^e Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

^f University of Kwa Zulu Natal, Kwa Zulu Natal, South Africa

^g Chris Hani Baragwanath Hospital, Johannesburg, South Africa

^h Edendale Hospital, Kwa Zulu Natal, South Africa

ⁱ Drugs for Neglected Diseases Initiative, Los Angeles, USA

^j David Geffen School of Medicine at UCLA, Los Angeles, USA

^k The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, USA

^l Centre for Global Health, Institute of Infection and Immunity, St George's University of London, London, UK

^m Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa

ⁿ Department of Infection and Immunity, St George's University of London, London, UK

^o Global Antibiotic Research and Development Partnership (GARDP), Cape Town, South Africa

^p Centre for Infectious Disease and Research, University of Cape Town, Cape Town, South Africa

ARTICLE INFO

Article history:

Received 24 December 2019

Received in revised form 24 February 2020

Accepted 26 February 2020

Keywords:

Flucytosine

SFC

Cryptococcal

Cryptococcal meningitis

Access

Access programme

Market failure

Public health

ABSTRACT

Background: Cryptococcal meningitis (CM) is estimated to cause 181 000 deaths annually, with the majority occurring in Sub-Saharan Africa. Flucytosine is recommended by the World Health Organization as part of the treatment for CM. Widespread use of flucytosine could reduce mortality in hospital by as much as 40% compared to the standard of care, yet due to market failure, quality-assured flucytosine remains unregistered and largely inaccessible throughout Africa.

Methods: The recently established South African flucytosine clinical access programme is an attempt to address the market failure that led to a lack of public sector access to flucytosine for CM, by making the medicine freely available to tertiary hospitals in South Africa.

Results: Between November 2018 and September 2019, 327 CM patients received flucytosine through this programme, with efforts to support sustainable national scale-up presently ongoing. We describe why this programme was needed, its catalytic potential, what is still required to ensure widespread access to flucytosine, and observations from this experience that may have wider relevance.

Conclusions: The South African flucytosine access programme illustrates how access programmes may be one part of the solution to addressing the vicious cycle of perceived low demand, limiting manufacturer interest in specific product markets.

© 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

The transition from phase 3 clinical trials demonstrating the efficacy of a medicine to widespread access in routine-care settings can be slow and tortuous, particularly for neglected diseases such as cryptococcal meningitis (CM) (Molloy et al., 2017). Here we

* Corresponding author: Amir Shroufi, Doctors Without Borders South Africa, Johannesburg, South Africa. E-mail: amir.shroufi@doctors.org.uk

outline the usefulness of clinical access programmes, one mechanism to bridge this period. The recently established South African flucytosine clinical access programme is an attempt to address the market failure that led to a lack of public sector access to flucytosine for CM. Initially, Médecins Sans Frontières (MSF) procured flucytosine with the support of South Africa's National Department of Health, under an import exemption (in terms of Section 21 of the Medicines and Related Substances Act, 101 of 1965) in order to supply this unregistered medicine to tertiary public sector hospitals in the country. We describe why this programme was needed, its catalytic potential, what is still required to ensure widespread access to flucytosine, and observations from this experience that may have wider relevance.

The South African flucytosine access programme

Flucytosine, in combination with amphotericin B, significantly reduces mortality among people living with HIV infection who suffer from CM. It has a favourable safety profile and allows the duration of amphotericin B infusion to be decreased, thus reducing toxicity (Kneale et al., 2016). Quality-assured flucytosine is, however, not registered in any country in Africa, the very place where it would be of most benefit (Molloy et al., 2018). In Sub-Saharan Africa, this medicine is commonly substituted by fluconazole, which is associated with inferior clinical outcomes (Kneale et al., 2016). Those who do not tolerate amphotericin B may receive even less effective fluconazole monotherapy. Flucytosine, developed in 1957, has been off patent for decades, yet the cost in the United States and other parts of the world has remained extraordinarily high because of manufacturer monopoly pricing (Merry and Boulware, 2016), at around 25 000 US dollars per 2-week treatment course (Micromedex Redbook). Manufacturers seem to perceive the market for flucytosine elsewhere as unattractive, while national departments of health have avoided its inclusion in guidelines and on essential medicines lists until registration is completed, the latter a lengthy and complicated process in many countries. This has meant that most people with CM continue to receive sub-standard therapy or no therapy at all, hindering efforts to reduce the estimated 140 000 annual CM deaths in Sub-Saharan Africa (Rajasingham et al., 2017).

Market failure with respect to flucytosine principally relates to issues at three levels: government, manufacturer, and provider, as outlined below.

(1) At the government level, this medicine appears to have been viewed as unaffordable (South African National Department of [Internet], 2016). This may have been exacerbated by the fact that manufacturers have not always been transparent on pricing (authors' personal efforts to obtain pricing information) or forthcoming with a reduced access price for the public sector (Thepharmaletter, 2018).

(2) On the manufacturer's side, the profit margins from low- and middle-income countries (LMICs) may not be perceived as substantial enough to justify investing the time and resources needed to file for registration and to scale up manufacturing and distribution. This is in contrast to the situation in North America, where the product is registered and available, albeit at a very high price. In addition, manufacturers have complained of poor demand; however this can only be generated if the product is registered and appears in guidelines in respective countries, a catch-22 situation.

(3) Providers are unfamiliar with the medicine so are less likely to seek to use it, even if available prior to registration off license. Flucytosine can be obtained in South Africa under the Section 21 exemption system. This has resulted in a vicious cycle where limited interest from end-users (clinicians treating people with HIV-associated CM) has led to weak and unarticulated demands

from government, which in turn has contributed to the perception of the market as unattractive, thus severely limiting patient access (Loyse et al., 2013).

The publication of the Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa (ACTA) trial results (Molloy et al., 2018; Wilson et al., 2018) has greatly strengthened calls to increase access to this medicine, with mortality reductions in the region of 40% reported at 10 weeks with the use of flucytosine (versus fluconazole) in induction therapy in combination with amphotericin B for CM. The magnitude of benefit and the strength of evidence has helped to shift the argument for flucytosine access to a humanitarian, as well as a scientific imperative.

The South African flucytosine clinical access programme was established in the second half of 2018 by MSF in conjunction with a range of key South African clinicians through the Southern African HIV Clinicians Society. It sought to ensure flucytosine supply to tertiary hospitals in South Africa, until such time as the medicine became available throughout the country. This has contributed to some modest successes. Between November 1, 2018 and September 1, 2019, we collected data on 327 patients treated within this programme. In-hospital mortality observed among CM patients treated during this period at supported sites was 25% during admission, compared to 36% mortality observed at the same sites prior to flucytosine introduction (GERMS South Africa Annual Report, 2017). While future more definitive comparisons will require adjustment for confounding, we provide these data to illustrate outcomes achievable with flucytosine in routine use.

Along with this limited access, the South African National Essential Medicines List Adult Hospital Level Medication Review Process recently concluded that flucytosine should form part of the preferred regimen for CM treatment, "pending South African Health Products Regulatory Authority (SAHPRA) registration with a reduction in price" (South African NDoH, 2018).

The situation with regard to flucytosine access remains precarious. While industry interest in the medicine is increasing, the medicine remains unregistered and this modest programme established in South Africa appears to have exhausted all stock that the principal manufacturer (Mylan) states can be provided in the short term. This programme may be thought of as a transitional access mechanism, having the potential both to facilitate wider access (the humanitarian perspective) and to produce evidence of a market and of the medicine's importance to public health.

The role of civil society

There are currently many other medicines of public health importance in LMICs with good evidence of efficacy but poor accessibility. These include directly acting antivirals (DAAs) for hepatitis C, delamanid for drug-resistant tuberculosis, and rifabutin for tuberculosis infection in patients with HIV.

In the early era of the AIDS epidemic, the unacceptability of poor access to antiretroviral therapy was prominent in the public discourse and led to vocal and effective civil society mobilization to demand fair access. Around the turn of the century, the treatment action campaign (TAC) and others mounted an effective 'defiance campaign', importing, alongside antiretrovirals, generic fluconazole at a time when the price of the registered originator version was a major impediment to accessing it for use in CM, with these efforts helping to catalyse wide systemic change (Ahmad, 2013). Such pressure would be useful now in the case of flucytosine and other essential but unavailable medicines, but is not currently seen in a vocal or impactful form.

The role of donors

We call upon funders to consider wider use of transitional access mechanisms such as clinical access programmes, given that they have the potential to provide data on the effectiveness and benefits of new regimens in real-world settings, establish the role of new medicines in high prevalence and resource-limited regions, create familiarity with use of the medicine among health care workers, and provide much needed access to patients while awaiting registration and routine use. Such programmes also bring wider attention, with the potential to promote meaningful dialogue between all vested stakeholders including civil society.

Through these activities it may be possible to demonstrate the presence of a market to manufacturers, while supporting earlier registration by providing locally derived data to relevant medicines regulators. By institutionalizing the role of such programmes and mechanisms, expedited access to medicines of public health importance in LMIC settings can become the norm rather than the exception. However, this will require a willingness to think outside typical paradigms, where non-governmental organizations (NGOs) seek simply to help government reach predetermined objectives, and other stakeholders passively await the availability of new medicines. Donors should recognize and maximally leverage their relative flexibility in this arena.

Potential pitfalls

We see such initiatives as distinct from manufacturer-sponsored and/or led donation programmes. Such programmes should be careful to balance the benefit to public health against the potential to distort or hinder market growth, and in so doing, hampering longer-term access.

Access programmes should not be viewed as an alternative to, but rather as leading to, the ultimate aim of sustainable widespread public sector access to medicines that have received regulatory approval and whose use will ultimately be integrated into routine programmes funded by national departments of health. Ensuring this transition necessitates close collaboration with departments of health throughout the process.

While such programmes may appear 'light' in comparison to a trial, they do require careful coordination around the logistics of supply, pharmacovigilance reporting, and follow-up with implementing sites; practical support from an organization with an implementation presence, such as MSF, may be useful in this regard.

Summary

The South African flucytosine access programme illustrates how access programmes may be one part of the solution to addressing the vicious cycle of perceived low demand, limiting manufacturer interest in specific product markets.

In the case of flucytosine, there remains an urgent need for generic manufacturers to file for registration and for the medicine to be included in national level guidelines, which will facilitate its use in the countries where it will have the most public health

impact. This requires continued sustained work from governments, civil society, and other non-governmental actors.

UNITAID will provide funds through a Clinton Health Access Initiative (CHAI) grant to ensure the continuation of the South African flucytosine clinical access programme. We hope that this will help encourage additional future investment in programmes to address market failure for key commodities needed in LMICs. We hope this experience will help such mechanisms to be more widely acknowledged as having a legitimate space in the medicine development and access continuum, particularly where the human costs of delayed access are so high.

Declarations

Ethical approval: None.

Conflict of interest: JN has undertaken paid consultancy work for Mylan and Cipla to advise them on antiretroviral options in South Africa. TSH has received an investigator award from Gilead Sciences, and speaker fees from Gilead Sciences and Pfizer.

References

- Ahmad H. The Treatment Action Campaign and the three dimensions of lawyering: reflections from the rainbow nation. *SAHARA J J Soc Asp HIV/AIDS Res Alliance* [Internet] 2013;10(1):17–24. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/23819672>.
- South GERMS. GERMS South Africa Annual Report National Institute for Communicable Diseases. 2017 GERMS South Africa Annual Report 2017. National Institute for Communicable Diseases. National Institute for Communicable Diseases. 2017;.
- Kneale M, Bartholomew JS, Davies E, Denning DW. J Antimicrob Chemother [Internet] 2016;3599–606. doi:<http://dx.doi.org/10.1093/jac/dkw325> Available from:.
- Loyse A, Dromer F, Day J. Nov. Lortholary O 2013;68(11):2435–44. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/23788479>.
- Merry M, Boulware D. Cryptococcal meningitis treatment strategies: a cost-effectiveness analysis in the United States affected by the explosive cost of flucytosine. *Clin Infect Dis*. 2016;23:.
- Molloy SF, Chiller T, Greene GS, Burry J, Govender NP, Kanyama C, et al. Cryptococcal meningitis: A neglected NTD? *PLoS Negl Trop Dis* [Internet] 2017;0005575. doi: <http://dx.doi.org/10.1371/journal.pntd.0005575> Available from:.
- Molloy SF, Kanyama C, Heyderman RS, Loyse A, Kouanfack C, Chanda D, N Engl J Med [Internet] 2018;1004–17. doi:<http://dx.doi.org/10.1056/NEJMoa1710922> Available from:.
- Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. *Lancet Infect Dis* [Internet] 2017;17(8):873–81 Available from: <https://www.ncbi.nlm.nih.gov/pubmed/28483415>.
- South African National Department of [Internet]. National Essential Medicines List Pharmacoeconomics and Budget impact analysis Adult Hospital Level Component : HIV and AIDS. 2016 Available from: <https://www.google.com/url?sa=t&rc=j&q=&esrc=s&source=web&cd=1&ved=2ahUKewjkn606qkAhW-ZUxUIHVbFBDQqFjAAegQIAxAC&url=http%3A%2F%2Fwww.health.gov.za%2Findex.php%2Fstandard-treatment-guidelines-and-essential-medicines-list%3Fdownload%3D2319%3Aanational-depa>.
- South African National Essential Medicine List Adult Hospital Level Medication Review Process Component. South African National Essential Medicine List Adult Hospital Level Medication Review Process Component: HIV and AIDS. . p. 1–10. *Thepharmaletter*. cited 2019 Aug 29]. 2018. Available from: <https://www.thepharmaletter.com/article/msf-warns-key-therapies-for-cryptococcal-disease-remain-out-of-reach-where-most-needed>.
- Wilson D, Loyse A, Burry J, Cohn J, Ford N, Chiller T, et al. Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries. *Lancet Infect Dis*. 2018;.

